Minerva Neurosciences Stock Price

0.06 (2.39%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Minerva Neurosciences Inc NERV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 2.39% 2.57 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.51 2.3758 2.55 2.54 2.51
Bid Price Ask Price Spread News
2.38 2.87 0.49 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,389 401,140 $ 2.46 $ 988,177 1,001,928 1.81 - 15.215
Last Trade Time Type Quantity Stock Price Currency
19:02:58 formt 250 $ 2.57 USD

Minerva Neurosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 109.67M 42.67M 30.20M $ - $ - -1.86 -6.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Minerva Neurosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NERV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.712.792.37582.49250,854-0.14-5.17%
1 Month3.133.1852.37582.81288,144-0.56-17.89%
3 Months3.143.69282.37583.20429,954-0.57-18.15%
6 Months3.334.1152.243.09627,686-0.76-22.82%
1 Year6.6315.2151.814.041,341,744-4.06-61.24%
3 Years6.9515.2151.814.95655,702-4.38-63.02%
5 Years6.2615.841.816.27531,597-3.69-58.95%

Minerva Neurosciences Description

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Your Recent History
Minerva Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.